Opus Genetics (IRD) Price & Analysis

Compare

1,149 Followers

IRD Stock Chart & Stats

$1.87

$0.08(5.63%)

At close: Jan 08 4:00 PM EST

$1.87

$0.08(5.63%)

Day’s Range― - ―

52-Week Range$0.65 - $2.16

Previous CloseN/A

Volume154.21K

Average Volume (3M)423.52K

Market Cap

$120.42M

Enterprise Value$28.28M

Total Cash (Recent Filing)$32.43M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Nov 18, 2025

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding59,908,054

10 Day Avg. Volume557,605

30 Day Avg. Volume423,516

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.23

Enterprise Value/Revenue1.83

Enterprise Value/Gross Profit2.26

Enterprise Value/Ebitda-0.48

Forecast

1Y Price Target

$7.67

Price Target Upside310.16% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsOPGx-LCA5 has exceeded expectations, with clinically significant & durable benefit on visual acuity as well as photoreceptor functionality per FST.

Funding And Financial PositionThe company's cash position is strong, with $32.4 million in cash and equivalents, and additional funding may arise, supporting operations into the future.

Market PerformanceThe company is likely to be an outperformer in the market, as per the belief of analysts hosting the Opus Genetics management team for a cocktail event.

Bears Say

Clinical Trial OutcomesOPGx-LCA5 did not consistently hit the targeted gain of 2+ objects across tested luminance levels and treatment time points.

Safety ConcernsAttention is being paid to any ocular irritations related to surgery or changes to retinal structure, which could impact safety.

Stock PerformanceThe stock experienced some weakness due to a few less important issues despite safety and efficacy being largely in line with expectations.

Opus Genetics News

Opus Genetics initiated with a Buy at Chardan

Chardan initiated coverage of Opus Genetics (IRD) with a Buy rating and $9 price target The firm cites...

3d ago

IRD

Opus Genetics reports pediatric data from OPGx-LCA5 Phase 1/2 trial

Opus Genetics (IRD) announced three-month data from the pediatric cohort of its ongoing Phase 1/2 clinical trial evaluating...

19d ago

IRD

Opus Genetics’ Promising Prospects: Buy Rating Reinforced by OPGx-LCA5 Efficacy and Strategic Advancements

Analyst Debanjana Chatterjee of JonesTrading reiterated a Buy rating on Opus Genetics, retaining the price target of $6.00....

19d ago

IRD

Opus Genetics Announces Positive Phase 1/2 Trial Results

The latest announcement is out from Opus Genetics ( ($IRD) ). On September 30, 2025, Opus Genetics announced...

19d ago

IRD

Opus Genetics reports inducement grant under Nasdaq listing rules

Opus Genetics (IRD) announced that the Compensation Committee of its Board of Directors approved equity awards under the...

1M ago

IRD

Promising Clinical Trial Results and Safety Profile Support Buy Rating for Opus Genetics

Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on Opus Genetics and keeping the price target at...

1M ago

IRD

Opus Genetics doses first patient in LYNX-3 Phase 3 trial

Opus Genetics (IRD) announced that the first patient has been dosed in LYNX-3, the Company’s Phase 3 clinical...

2M ago

IRD

Opus Genetics Appoints New Chief Financial Officer

Opus Genetics ( ($IRD) ) has shared an update. Opus Genetics announced the appointment of Rob Gagnon as...

2M ago

IRD

Opus Genetics appoints Rob Gagnon as CFO

Opus Genetics (IRD) announced the appointment of Rob Gagnon, CPA, MBA, as CFO. Gagnon joins Opus from Remix...

2M ago

IRD

Promising Developments and Financial Stability Drive Buy Rating for Opus Genetics

Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from...

2M ago

IRD

Opus Genetics announces FDA clearance of IND application for OPGx-BEST1

Opus Genetics (IRD) announced that the U.S. Food and Drug Administration, FDA, has accepted its Investigational New Drug,...

2M ago

IRD

Opus Genetics: Promising Clinical Trials and Strategic Partnerships Drive Buy Rating

Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield from...

2M ago

IRD

Opus Genetics reports Q2 EPS (12c) vs (30c) last year

Reports Q2 revenue $2.9M, consensus $4.27M. “We’ve made significant progress across our pipeline, with multiple clinical and regulatory...

2M ago

IRD

Opus Genetics Secures Funding for Gene Therapy Development

Opus Genetics ( ($IRD) ) has shared an announcement. On July 22, 2025, Opus Genetics entered into a...

3M ago

IRD

IRD FAQ

What was Opus Genetics’s price range in the past 12 months?

Opus Genetics lowest stock price was $0.65 and its highest was $2.16 in the past 12 months.

What is Opus Genetics’s market cap?

Opus Genetics’s market cap is $120.42M.

When is Opus Genetics’s upcoming earnings report date?

Opus Genetics’s upcoming earnings report date is Nov 18, 2025 which is in 30 days.

How were Opus Genetics’s earnings last quarter?

Opus Genetics released its earnings results on Aug 13, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.205 by $0.085.

Is Opus Genetics overvalued?

According to Wall Street analysts Opus Genetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Opus Genetics pay dividends?

Opus Genetics does not currently pay dividends.

What is Opus Genetics’s EPS estimate?

Opus Genetics’s EPS estimate is -0.13.

How many shares outstanding does Opus Genetics have?

Opus Genetics has 59,908,054 shares outstanding.

What happened to Opus Genetics’s price movement after its last earnings report?

Opus Genetics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.205. Following the earnings report the stock price went up 7.273%.

Which hedge fund is a major shareholder of Opus Genetics?

Currently, no hedge funds are holding shares in IRD

Opus Genetics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-200.57%

Trailing 12-Months

Asset Growth

-13.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opus Genetics

Opus Genetics (IRD) is a biotechnology company focused on developing gene therapies for inherited retinal diseases. The company operates within the biopharmaceutical sector, concentrating on creating innovative treatments aimed at restoring vision for patients affected by genetic eye disorders. Its core products are gene therapy solutions that target specific genetic mutations responsible for retinal diseases.

Opus Genetics (IRD) Earnings & Revenues

Historic Earnings Reports

IRD Stock 12 Month Forecast

Average Price Target

$7.67

▲(310.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.8,2.353846153846154,2.907692307692308,3.4615384615384617,4.015384615384615,4.569230769230769,5.1230769230769235,5.676923076923077,6.230769230769231,6.7846153846153845,7.338461538461538,7.892307692307693,8.446153846153846,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.8,2.2515384615384617,2.703076923076923,3.1546153846153846,3.6061538461538465,4.0576923076923075,4.509230769230769,4.960769230769231,5.412307692307692,5.863846153846154,6.315384615384615,6.766923076923077,7.218461538461539,{"y":7.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.8,2.123076923076923,2.4461538461538463,2.769230769230769,3.0923076923076924,3.4153846153846157,3.7384615384615385,4.061538461538461,4.384615384615385,4.707692307692308,5.030769230769231,5.353846153846154,5.676923076923077,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >